type here...

The New York Times

12345Page 3 of 5

LATEST NEWS

Antitrust and Competition

Paid to Show the Drug Works: Why “Blind” Clinical Trials for New Drugs are Far Less Blind Than They Should Be

Jessie Wrobel
New research shows that physicians in industry-sponsored trials are more captured by pharmaceutical companies than physicians in unsponsored ones.
Read more
COMMENTARIES

Bethany McLean’s Weekend Reading List: Elder Care Facilities, Twitter, and Pot

Bethany McLean
Corruption, lobbying, corporate malfeasance, and frauds: a weekly unconventional selection of must-read articles by investigative journalist Bethany McLean. 
Read more
Antitrust and Competition

It Is Such a Small World: The Market-Design Academic Community Evolved in a Business Network

Stefano Feltri
Private equity funds such as Michael Dell's MSD Capital made hundreds of millions of dollars in profits from the 2017 FCC spectrum...
Read more
Antitrust and Competition

How Market Design Economists Helped to Engineer a Mass Privatization of Public Resources

Glen Weyl
In 2017, the Federal Communications Commission conducted a complex two-sided auction to reallocate spectrum from broadcasters to mobile communications companies. The way...
Read more
Alberto Alesina

How Alberto Alesina Challenged the Median Voter Theorem

Howard Rosenthal
"Alberto Alesina's insight was that the economy was driven neither by the opportunistic behavior of politicians nor by the pursuit of partisan...
Read more

ProMarket is dedicated to discussing how competition tends to be subverted by special interests. The posts represent the opinions of their writers, not necessarily those of the University of Chicago, the Booth School of Business, or its faculty. For more information, please visit ProMarket Policy.

About Us

Categories

Antitrust and CompetitionRegulatory CaptureMediaRent seekingMoney in PoliticsCorporate Governance